SG11202102683XA - Treatment for obesity - Google Patents
Treatment for obesityInfo
- Publication number
- SG11202102683XA SG11202102683XA SG11202102683XA SG11202102683XA SG11202102683XA SG 11202102683X A SG11202102683X A SG 11202102683XA SG 11202102683X A SG11202102683X A SG 11202102683XA SG 11202102683X A SG11202102683X A SG 11202102683XA SG 11202102683X A SG11202102683X A SG 11202102683XA
- Authority
- SG
- Singapore
- Prior art keywords
- obesity
- treatment
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Reverberation, Karaoke And Other Acoustics (AREA)
- Materials For Photolithography (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862732650P | 2018-09-18 | 2018-09-18 | |
| PCT/US2019/051788 WO2020061231A1 (en) | 2018-09-18 | 2019-09-18 | Treatment for obesity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202102683XA true SG11202102683XA (en) | 2021-04-29 |
Family
ID=69888828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202102683XA SG11202102683XA (en) | 2018-09-18 | 2019-09-18 | Treatment for obesity |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210275523A1 (ja) |
| EP (1) | EP3852754A4 (ja) |
| JP (1) | JP2022501435A (ja) |
| KR (1) | KR20210080378A (ja) |
| CN (2) | CN112996507B (ja) |
| AU (1) | AU2019343922B2 (ja) |
| CA (1) | CA3113014A1 (ja) |
| SG (1) | SG11202102683XA (ja) |
| TW (1) | TWI839385B (ja) |
| WO (1) | WO2020061231A1 (ja) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3852753A4 (en) * | 2018-09-18 | 2022-06-08 | 1Globe Biomedical Co., Ltd. | TREATMENT OF NONALCOHOLIC FAT LIVER DISEASE |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9716557D0 (en) * | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| WO2007011702A2 (en) * | 2005-07-15 | 2007-01-25 | The University Of North Carolina At Chapel Hill | Use of egfr inhibitors to prevent or treat obesity |
| EP3037419B1 (en) * | 2007-09-06 | 2019-09-04 | Boston Biomedical, Inc. | Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases |
| SG11201507346PA (en) * | 2013-03-13 | 2015-10-29 | Boston Biomedical Inc | 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer |
| US9187454B2 (en) * | 2013-03-13 | 2015-11-17 | Boston Biomedical, Inc. | Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof |
| WO2014202528A1 (en) * | 2013-06-20 | 2014-12-24 | Boehringer Ingelheim International Gmbh | Olefin substituted oxindoles having ampk activity |
| EP2886541A1 (en) * | 2013-12-19 | 2015-06-24 | Sanofi | Oxindole derivatives, preparation thereof and therapeutic use in the treatment of AMPK-related diseases |
| MX2016009655A (es) * | 2014-01-27 | 2016-11-09 | Boston Biomedical Inc | Metodos novedosos para el tratamiento del cancer. |
| JP2018514572A (ja) * | 2015-04-30 | 2018-06-07 | エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント | オキシンドール化合物およびその医薬組成物 |
| US10377749B2 (en) * | 2015-08-10 | 2019-08-13 | Sumitomo Dainippon Pharma Co., Ltd. | Purification method for 5-(thiazol-4-yl)indolin-2-one derivative |
-
2019
- 2019-09-18 KR KR1020217011269A patent/KR20210080378A/ko unknown
- 2019-09-18 US US17/276,821 patent/US20210275523A1/en active Pending
- 2019-09-18 CA CA3113014A patent/CA3113014A1/en active Pending
- 2019-09-18 JP JP2021539500A patent/JP2022501435A/ja active Pending
- 2019-09-18 SG SG11202102683XA patent/SG11202102683XA/en unknown
- 2019-09-18 CN CN201980061265.3A patent/CN112996507B/zh active Active
- 2019-09-18 TW TW108133699A patent/TWI839385B/zh active
- 2019-09-18 EP EP19862078.3A patent/EP3852754A4/en active Pending
- 2019-09-18 WO PCT/US2019/051788 patent/WO2020061231A1/en active Application Filing
- 2019-09-18 CN CN202311028448.XA patent/CN117224541A/zh active Pending
- 2019-09-18 AU AU2019343922A patent/AU2019343922B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN117224541A (zh) | 2023-12-15 |
| TWI839385B (zh) | 2024-04-21 |
| CA3113014A1 (en) | 2020-03-26 |
| CN112996507A (zh) | 2021-06-18 |
| TW202034911A (zh) | 2020-10-01 |
| AU2019343922A1 (en) | 2021-04-29 |
| CN112996507B (zh) | 2023-09-05 |
| JP2022501435A (ja) | 2022-01-06 |
| EP3852754A1 (en) | 2021-07-28 |
| AU2019343922B2 (en) | 2024-01-25 |
| US20210275523A1 (en) | 2021-09-09 |
| WO2020061231A1 (en) | 2020-03-26 |
| KR20210080378A (ko) | 2021-06-30 |
| EP3852754A4 (en) | 2022-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201813876D0 (en) | Treatment | |
| EP3761918C0 (en) | ORTHOTIC DEVICE | |
| GB201811679D0 (en) | Treatment apparatus | |
| IL281792A (en) | Treatment methods | |
| IL282958A (en) | Combined treatment of resistant hypertension | |
| GB201800546D0 (en) | Treatment | |
| IL281839A (en) | Treatment methods | |
| SG11202102683XA (en) | Treatment for obesity | |
| GB201914296D0 (en) | Treatment | |
| ZA201905904B (en) | Device for sewage treatment | |
| SG10201913381PA (en) | Treatment apparatus | |
| GB201804763D0 (en) | Gout treatment | |
| GB201816929D0 (en) | Obesity | |
| GB201814905D0 (en) | Treatment | |
| SG10201910408QA (en) | Device for treating dysarthrosis | |
| IL279951A (en) | A device for treating a reaction | |
| GB201803494D0 (en) | Treatment regime | |
| GB201912760D0 (en) | Treatment | |
| GB201912365D0 (en) | Treatment | |
| GB201912335D0 (en) | Treatment | |
| GB201911816D0 (en) | Treatment | |
| GB201911603D0 (en) | Treatment | |
| GB201910755D0 (en) | Treatment | |
| GB201904253D0 (en) | Treatment | |
| GB201902579D0 (en) | Treatment |